Skip to main content

Table 4 Linear model for annual change in FVC (L), DLco (mmol/kPa/min) and CPI

From: The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

All data are given as:

Total

NIN

NAF

P1

mean (95% CI), p-value

N = 611

 N = 430

 N = 181

Annual rate of change

    

FVC (l/yr)

-0.024 (-0.047; 0), p = 0.050

-0.014 (-0.041; 0.012), p = 0.295

-0.058 (-0.108; -0.008), p = 0.022

p = 0.130

DLco (mmol/kPa/min/yr)

-0.245 (-0.296; -0.195), p < 0.001

-0.27 (-0.327; -0.214), p < 0.001

-0.149 (-0.26; -0.038), p = 0.008

p = 0.056

CPI (per yr)

1.307 (0.584; 2.029), p < 0.001

1.185 (0.352; 2.018), p = 0.006

1.592 (0.124; 3.059), p = 0.034

p = 0.637

Annual rate of change (adjusted2)

    

FVC (l/yr)

-0.014 (-0.044; 0.017), p = 0.387

0.002 (-0.033; 0.037), p = 0.920

-0.056 (-0.117; 0.005), p = 0.071

p = 0.108

DLco (mmol/kPa/min/yr)

-0.241 (-0.301; -0.18), p < 0.001

-0.266 (-0.335; -0.197), p < 0.001

-0.165 (-0.289; -0.04), p = 0.009

p = 0.163

CPI (per yr)

1.403 (0.451; 2.355), p = 0.004

1.192 (0.091; 2.293), p = 0.035

1.999 (0.102; 3.896), p = 0.039

p = 0.472

  1. NIN – patients treated with nintedanib; NAF – patients with no-antifibrotic treatment
  2. 1 statistical significance of the interaction between time and treatment from the linear mixed-effects model; only follow-up visits within 24 months from baseline were included into the model
  3. 2 adjusted for sex, age and baseline level (FVC, DLco or CPI, respectively)